Connection

Chong Yu to Drug Resistance, Neoplasm

Back to Details
This is a "connection" page, showing publications Chong Yu has written about Drug Resistance, Neoplasm.
Chong Yu
Connection Strength
0.714
Drug Resistance, Neoplasm
  1. Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations. Int J Cancer. 2019 06 01; 144(11):2887-2896.
    View in: PubMed
    Score: 0.572
  2. EGFR-Mutant SCLC Exhibits Heterogeneous Phenotypes and Resistance to Common Antineoplastic Drugs. J Thorac Oncol. 2019 03; 14(3):513-526.
    View in: PubMed
    Score: 0.142
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.